{"DataElement":{"publicId":"14305189","version":"1","preferredName":"First Antipneumocystis Agent Prophylaxis Administered Type","preferredDefinition":"A description of the first antipneumocystis agent administered as prophylaxis.","longName":"14305185v1.00:5081195v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"14305185","version":"1","preferredName":"First Antipneumocystis Agent Preventive Intervention Administered","preferredDefinition":"Preceding all others in time or space or degree._Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).:Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._The act of having given something (e.g., a medication or test).","longName":"7625599v1.00:6775332v1.00","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7625599","version":"1","preferredName":"First Antipneumocystis Agent","preferredDefinition":"Preceding all others in time or space or degree.:Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","longName":"C25509:C124791","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF002A45-7425-4480-E053-4EBD850A447D","latestVersionIndicator":"Yes","beginDate":"2021-04-02","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-02","modifiedBy":"ONEDATA","dateModified":"2021-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6775332","version":"1","preferredName":"Preventive Intervention Administered","preferredDefinition":"In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).:The act of having given something (e.g., a medication or test).","longName":"C15843:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A9A31E8-867D-1ABA-E053-F662850AACC0","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"025BE6A9-4D3D-29BE-E063-731AD00A2904","latestVersionIndicator":"Yes","beginDate":"2023-08-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-07","modifiedBy":"KUMMEROA","dateModified":"2023-10-06","changeDescription":null,"administrativeNotes":"2023.10.6 Released per ticket request CADSR0002930. ak2023.8.7 Created per ticket request CADSR0002666. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5081195","version":"1","preferredName":"Antipneumocystis Agent Type","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP)._Something distinguishable as an identifiable class based on common qualities.","longName":"5081195v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BCCD-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Other anti-pneumocystis","valueDescription":"Other Antipneumocystis Agent","ValueMeaning":{"publicId":"5081196","version":"1","preferredName":"Other Antipneumocystis Agent","longName":"5081196","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCDA-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BCF3-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Pentamidine IV","valueDescription":"Intravenous Route of Administration Pentamidine","ValueMeaning":{"publicId":"5081197","version":"1","preferredName":"Intravenous Route of Administration Pentamidine","longName":"5081197","preferredDefinition":"Administration within or into a vein or veins.: A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD00-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD19-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Pentamidine inhaled","valueDescription":"Inhalation Route of Administration Pentamidine","ValueMeaning":{"publicId":"5081198","version":"1","preferredName":"Inhalation Route of Administration Pentamidine","longName":"5081198","preferredDefinition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.: A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation Route of Administration","conceptCode":"C38216","definition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD26-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD3F-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Dapsone","valueDescription":"Dapsone","ValueMeaning":{"publicId":"5081199","version":"1","preferredName":"Dapsone","longName":"5081199","preferredDefinition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapsone","conceptCode":"C415","definition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD49-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD61-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Atovaquone","valueDescription":"Atovoquone","ValueMeaning":{"publicId":"2575655","version":"1","preferredName":"Atovoquone","longName":"2575655","preferredDefinition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atovaquone","conceptCode":"C28838","definition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F494-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"CURTIST","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD6B-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Trimethoprim/Sulfamethoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"5081200","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"5081200","preferredDefinition":"An antibiotic drug used to treat infection and prevent pneumocystis carinii pneumonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD75-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD8D-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5081194","version":"1","preferredName":"Antipneumocystis Agent Type","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).:Something distinguishable as an identifiable class based on common qualities.","longName":"C124791:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCA6-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCB7-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_IP_frst_antipne_pro_agt","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the first antipneumocystis agent administered as prophylaxis?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Specify the first anti-pneumocystis (PJP) drug given as prophylaxis","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"025C3BD4-B417-3F84-E063-731AD00A81D3","latestVersionIndicator":"Yes","beginDate":"2023-08-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-07","modifiedBy":"KUMMEROA","dateModified":"2023-10-06","changeDescription":null,"administrativeNotes":"2023.10.6 Released per ticket request CADSR0002930. ak2023.8.24 Alt Name added per ticket request CADSR0002778. ak 2023.8.7 Created per ticket request CADSR0002666. ak","unresolvedIssues":null,"deletedIndicator":"No"}}